Fudenberg, H.H. Italian Review of Medical and Surgical Researches (editorial) 2(4):65-71 (1998)

The ethics and efficacy of AIDS vaccine trials have been questioned both in scientific journals and in periodicals read by intelligent laymen in the U.S. and abroad. Of particular concen is that the gp120 vaccine may CAUSE rather than PREVENT clincial AIDS. Despite the apparent success of the new triple "Highly Active Anti-Retroviral Therapy" (HAART: a reverse-transcriptase inhibitor plus 2 anti-proteases), no more than 50% of the patients can reduce the HIV in their blood to undetectable levels when the most highly sensitive tests are used, and HIV levels are greatly reduced in blood long before they are in total body, since the virus binds to the tips of the dendritic cells in the tonsils, spleen, etc., beyond the reach of the HAART rugs. Furthermore, no more than 50% of patients on such combinations can tolerate them; severe drug interactions may occur with cardiac medications, anti-coagulants, hypnotics, anti-depressants, etc. In contrast, HIV-specific Transfer Factor (TF) has in the past produced excellent results in reducing HIV loads, originally 260,000/mm3 to 50,000/mm3, in patients who contracted the virus via blood transfusion or promiscuous sex, to 0 by PCR (old method, standard error 1/2 log), in causing disappearance of afternoon fevers, anorexia, and weight loss, in causing 80% 5-year survival of severely ill AIDS patients with prior expected life span of 6-12 months, and in development of delayed cutaneous hypersensitivity in previously anergic patients by 60 days.